Zobrazeno 1 - 10
of 2 481
pro vyhledávání: '"S Esfahani"'
Autor:
Mohammad S. Esfahani, Luke J. Lee, Young-Jun Jeon, Ryan A. Flynn, Henning Stehr, Angela B. Hui, Noriko Ishisoko, Eric Kildebeck, Aaron M. Newman, Scott V. Bratman, Matthew H. Porteus, Howard Y. Chang, Ash A. Alizadeh, Maximilian Diehn
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
The authors report a co-occurrence of the U2AF1 S34F splicing factor mutation and ROS1 translocations in lung adenocarcinomas and profile effects of S34F on transcriptome-wide RNA binding. They further show that U2AF1 S34F enhances invasive potential
Externí odkaz:
https://doaj.org/article/0437a662c77043ed87f4f0be71eb3a88
Autor:
Viswam S. Nair, Angela Bik-Yu Hui, Jacob J. Chabon, Mohammad S. Esfahani, Henning Stehr, Barzin Y. Nabet, Li Zhou, Aadel A. Chaudhuri, Jalen Benson, Kelsey Ayers, Harmeet Bedi, Meghan Ramsey, Ryan Van Wert, Sanja Antic, Natalie Lui, Leah Backhus, Mark Berry, Arthur W. Sung, Pierre P. Massion, Joseph B. Shrager, Ash A. Alizadeh, Maximilian Diehn
Publikováno v:
Cancer Research. 82:2838-2847
Genomic profiling of bronchoalveolar lavage (BAL) samples may be useful for tumor profiling and diagnosis in the clinic. Here, we compared tumor-derived mutations detected in BAL samples from subjects with non–small cell lung cancer (NSCLC) to thos
Autor:
E.D. Abston, I. Zhou, S. Shuvaev, E. Akam, J. Saenger, S. Esfahani, N. Rotile, L.P. Hariri, F.J. Fintelmann, C. Catana, P. Caravan, M. Lanuti
Publikováno v:
C28. FROM OMICS TO EX VIVO MODELS: A ROAD MAP FOR NOVEL THERAPIES IN LUNG FIBROSIS.
Autor:
Maximilian Diehn, Ash A. Alizadeh, Joseph C. Liao, Mandy L.Y. Sin, Barzin Y. Nabet, Helio A. Costa, Harumi Lim, Chih Long Liu, Henning Stehr, Aadel A. Chaudhuri, Jacob J. Chabon, Dharati Trivedi, Mohammad S. Esfahani, Simon B. Chen, William Y. Shi, Daniel V. Lazzareschi, Joseph Schroers-Martin, Jonathan C. Dudley
Supplemental Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b5bcfbb1cb23e976565fa82373056e8
https://doi.org/10.1158/2159-8290.22532998
https://doi.org/10.1158/2159-8290.22532998
Autor:
Maximilian Diehn, Ash A. Alizadeh, Joseph C. Liao, Mandy L.Y. Sin, Barzin Y. Nabet, Helio A. Costa, Harumi Lim, Chih Long Liu, Henning Stehr, Aadel A. Chaudhuri, Jacob J. Chabon, Dharati Trivedi, Mohammad S. Esfahani, Simon B. Chen, William Y. Shi, Daniel V. Lazzareschi, Joseph Schroers-Martin, Jonathan C. Dudley
Supplemental Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d03cd713f3fa1d092b5a412f4f2abe
https://doi.org/10.1158/2159-8290.22532992.v1
https://doi.org/10.1158/2159-8290.22532992.v1
Autor:
Maximilian Diehn, Ash A. Alizadeh, Joseph B. Shrager, Pierre P. Massion, Arthur W. Sung, Mark Berry, Leah Backhus, Natalie Lui, Sanja Antic, Ryan Van Wert, Meghan Ramsey, Harmeet Bedi, Kelsey Ayers, Jalen Benson, Aadel A. Chaudhuri, Li Zhou, Barzin Y. Nabet, Henning Stehr, Mohammad S. Esfahani, Jacob J. Chabon, Angela Bik-Yu Hui, Viswam S. Nair
Genomic profiling of bronchoalveolar lavage (BAL) samples may be useful for tumor profiling and diagnosis in the clinic. Here, we compared tumor-derived mutations detected in BAL samples from subjects with non–small cell lung cancer (NSCLC) to thos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caa701659e31e5025f8d9c2a3cc6d32a
https://doi.org/10.1158/0008-5472.c.6514103.v1
https://doi.org/10.1158/0008-5472.c.6514103.v1
Autor:
Maximilian Diehn, Ash A. Alizadeh, Joseph B. Shrager, Pierre P. Massion, Arthur W. Sung, Mark Berry, Leah Backhus, Natalie Lui, Sanja Antic, Ryan Van Wert, Meghan Ramsey, Harmeet Bedi, Kelsey Ayers, Jalen Benson, Aadel A. Chaudhuri, Li Zhou, Barzin Y. Nabet, Henning Stehr, Mohammad S. Esfahani, Jacob J. Chabon, Angela Bik-Yu Hui, Viswam S. Nair
Supplementary Figure from Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0368b5a441238a2c888e1b3af79b4c57
https://doi.org/10.1158/0008-5472.22432262.v1
https://doi.org/10.1158/0008-5472.22432262.v1
Autor:
Maximilian Diehn, Ash A. Alizadeh, Joseph B. Shrager, Pierre P. Massion, Arthur W. Sung, Mark Berry, Leah Backhus, Natalie Lui, Sanja Antic, Ryan Van Wert, Meghan Ramsey, Harmeet Bedi, Kelsey Ayers, Jalen Benson, Aadel A. Chaudhuri, Li Zhou, Barzin Y. Nabet, Henning Stehr, Mohammad S. Esfahani, Jacob J. Chabon, Angela Bik-Yu Hui, Viswam S. Nair
Supplementary Data from Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d817bcbe95478dc7ae5e4d877288aac
https://doi.org/10.1158/0008-5472.22432274
https://doi.org/10.1158/0008-5472.22432274
Autor:
Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad S. Esfahani, Aaron M. Newman, Henry J. Haringsma, David M. Kurtz, Henning Stehr, Florian Scherer, Chris A. Karlovich, Thomas C. Harding, Kathleen A. Durkin, Gregory A. Otterson, W. Thomas Purcell, D. Ross Camidge, Jonathan W. Goldman, Lecia V. Sequist, Zofia Piotrowska, Heather A. Wakelee, Joel W. Neal, Ash A. Alizadeh, Maximilian Diehn
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-15 (2016)
EGFR-mutant non-small cell lung cancer is routinely treated with EGFR inhibitors, although resistance inevitably develops. Here, the authors sequence circulating tumour DNA and show that resistance to the third-generation inhibitor rociletinib is het
Externí odkaz:
https://doaj.org/article/e467721976a7414699480c405cfa9845
Autor:
Jurik A. Mutter, Stefan K. Alig, Mohammad S. Esfahani, Eliza M. Lauer, Jan Mitschke, David M. Kurtz, Julia Kühn, Sabine Bleul, Mari Olsen, Chih Long Liu, Michael C. Jin, Charles W. Macaulay, Nicolas Neidert, Timo Volk, Michel Eisenblaetter, Sebastian Rauer, Dieter H. Heiland, Jürgen Finke, Justus Duyster, Julius Wehrle, Marco Prinz, Gerald Illerhaus, Peter C. Reinacher, Elisabeth Schorb, Maximilian Diehn, Ash A. Alizadeh, Florian Scherer
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
PURPOSE Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably heterogeneous, yet identification of patients at high risk for treatment failure is challenging. Furthermore, CNSL diagnosis often remains unconfirmed because of contrain